» Articles » PMID: 33311634

Structural and Functional Comparison of SARS-CoV-2-spike Receptor Binding Domain Produced in Pichia Pastoris and Mammalian Cells

Overview
Journal Sci Rep
Specialty Science
Date 2020 Dec 14
PMID 33311634
Citations 63
Affiliations
Soon will be listed here.
Abstract

The yeast Pichia pastoris is a cost-effective and easily scalable system for recombinant protein production. In this work we compared the conformation of the receptor binding domain (RBD) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Spike protein expressed in P. pastoris and in the well established HEK-293T mammalian cell system. RBD obtained from both yeast and mammalian cells was properly folded, as indicated by UV-absorption, circular dichroism and tryptophan fluorescence. They also had similar stability, as indicated by temperature-induced unfolding (observed T were 50 °C and 52 °C for RBD produced in P. pastoris and HEK-293T cells, respectively). Moreover, the stability of both variants was similarly reduced when the ionic strength was increased, in agreement with a computational analysis predicting that a set of ionic interactions may stabilize RBD structure. Further characterization by high-performance liquid chromatography, size-exclusion chromatography and mass spectrometry revealed a higher heterogeneity of RBD expressed in P. pastoris relative to that produced in HEK-293T cells, which disappeared after enzymatic removal of glycans. The production of RBD in P. pastoris was scaled-up in a bioreactor, with yields above 45 mg/L of 90% pure protein, thus potentially allowing large scale immunizations to produce neutralizing antibodies, as well as the large scale production of serological tests for SARS-CoV-2.

Citing Articles

A Live-Cell Imaging-Based Fluorescent SARS-CoV-2 Neutralization Assay by Antibody-Mediated Blockage of Receptor Binding Domain-ACE2 Interaction.

Arias-Arias J, Monturiol-Gross L, Corrales-Aguilar E BioTech (Basel). 2025; 14(1).

PMID: 39982277 PMC: 11843899. DOI: 10.3390/biotech14010010.


Protein Expression Platforms and the Challenges of Viral Antigen Production.

Sookhoo J, Schiffman Z, Ambagala A, Kobasa D, Pardee K, Babiuk S Vaccines (Basel). 2025; 12(12.

PMID: 39772006 PMC: 11680109. DOI: 10.3390/vaccines12121344.


Designing strong inducible synthetic promoters in yeasts.

Tominaga M, Shima Y, Nozaki K, Ito Y, Someda M, Shoya Y Nat Commun. 2024; 15(1):10653.

PMID: 39702268 PMC: 11659477. DOI: 10.1038/s41467-024-54865-z.


Backstage Heroes-Yeast in COVID-19 Research.

Grabinski W, Karachitos A, Kicinska A Int J Mol Sci. 2024; 25(23.

PMID: 39684373 PMC: 11640846. DOI: 10.3390/ijms252312661.


Highly selective split intein method for efficient separation and purification of recombinant therapeutic proteins from mammalian cell culture fluid.

Prabhala S, Marshall B, Galiardi J, Fan Y, Creamer E, Wood D J Chromatogr A. 2024; 1736:465430.

PMID: 39405639 PMC: 11533640. DOI: 10.1016/j.chroma.2024.465430.


References
1.
Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

2.
DAlessio C, Caramelo J, Parodi A . UDP-GlC:glycoprotein glucosyltransferase-glucosidase II, the ying-yang of the ER quality control. Semin Cell Dev Biol. 2010; 21(5):491-9. PMC: 2883647. DOI: 10.1016/j.semcdb.2009.12.014. View

3.
Zhang T, Wu Q, Zhang Z . Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr Biol. 2020; 30(7):1346-1351.e2. PMC: 7156161. DOI: 10.1016/j.cub.2020.03.022. View

4.
Deutsch E, Mendoza L, Shteynberg D, Farrah T, Lam H, Tasman N . A guided tour of the Trans-Proteomic Pipeline. Proteomics. 2010; 10(6):1150-9. PMC: 3017125. DOI: 10.1002/pmic.200900375. View

5.
Shajahan A, Supekar N, Gleinich A, Azadi P . Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology. 2020; 30(12):981-988. PMC: 7239183. DOI: 10.1093/glycob/cwaa042. View